News

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval to the extension of the existing indication of Xydalba (dalbavancin) to include the pediatric population.

This project will contribute to sustainable development of pharmaceutical manufacture, use and disposal.

In Spain alone, it is estimated that 400,000 people suffer from epilepsy, a chronic disease that affects more than 50 million people worldwide.

On World Mental Health Day 2022, with the goal of raising awareness around mental health disorders, Angelini Pharma announces its partnership with the on-demand streaming platform CHILI.

A new recognition for Angelini Pharma, confirming once again its commitment to becoming a workplace that is increasingly focused on people's wellbeing.

Angelini Pharma celebrates the event through the words of its researchers.

The presentation event for the new Mental Health Index will be held in Brussels on Sept. 28 and will be available via live streaming on the Harmonia mentis website.

Headway | Focus Epilepsy was conceived to create a multidisciplinary platform for strategic consideration, analysis, dialogue, and comparison between various European experiences in epilepsy management.

Sustainability has become one of the most relevant concepts as it is also intertwined with health. The pandemic unequivocally showed us that there is in fact a correlation between environment and our wellbeing.

The last few turbulent years have accelerated organizations’ digital transformation and Angelini Pharma has embraced this change to become a Digital First company.